Retinal Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Retinal transplant immunology and advancements.
Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation.
Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye.
Gene therapy and genome surgery in the retina.
Optical coherence tomography angiography.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2025-12-24A Multi-Center, Randomized, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VGR-R01 in Subjects With Bietti Crystalline DystrophyResults expected Q4 2026
- 2025-12-18Efficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular DegenerationResults expected Q4 2027
- 2026-06-01Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)Primary completion
- 2025-12-01A Phase 1/2, Open-label, Multi-national, Multiple-cohort, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of HG004 Gene Therapy in Subjects with RPE65-associated Leber Congenital Amaurosis Type 2 (LCA2)Primary completion
- 2026-06-01ClinicalPhase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis)Primary completion
- 2025-12-24ClinicalA Multi-Center, Randomized, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VGR-R01 in Subjects With Bietti Crystalline DystrophyResults expected Q4 2026
- 2025-12-18ClinicalEfficacy of Dapagliflozin in the Progression of Geographic Atrophy Secondary to Age-Related Macular DegenerationResults expected Q4 2027
- 2025-12-01ClinicalA Phase 1/2, Open-label, Multi-national, Multiple-cohort, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of HG004 Gene Therapy in Subjects with RPE65-associated Leber Congenital Amaurosis Type 2 (LCA2)Primary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Retinal Diseases3
- Diabetic Retinopathy2
- CRISPR-Cas Systems1
- Dependovirus1
- Diabetes Mellitus1
- Diagnostic Techniques, Ophthalmological1
- DNA Mutational Analysis1
- Eye Diseases1
Leading journals6
- American journal of human genetics1
- Diabetologia1
- International journal of molecular sciences1
- Molecular therapy : the journal of the American Society of Gene Therapy1
- Pharmaceutical research1
- Progress in retinal and eye research1
Leading researchers8
- Allen L1
- Alvarez D1
- Armstrong R1
- Arno G1
- Bitner-Glindzicz M1
- Brady AF1
- Carmichael J1
- Carss KJ1
Affiliations (unnormalised)6
- University of Cambridge2
- Cambridge University Hospitals NHS Foundation Trust1
- Department of Electrical Engineering & Computer Science and Research Laboratory of Electronics1
- Diabetes Research Centre1
- Doheny Eye Institute1
- Duke University Medical Center1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Retinal diseases are disorders that involve the retina. The supplied literature frames them as a broad group that includes inherited retinal disorders, vascular retinal disease, and inflammatory retinal injury, with major relevance to vision loss.
The grounding supports genetic causes for some retinal diseases, including mutations in single genes such as RPE65. It also supports vascular and inflammatory contributors, and in diabetic retinopathy specifically, microvascular complications of diabetes are implicated.
Retinal disease mechanisms in the supplied literature include disrupted retinal blood flow and microvascular dysfunction, inflammatory activation after loss of retinal immune privilege, and pathology arising from pathogenic genetic variants. The literature also emphasizes retinal metabolism and the use of gene delivery or genome editing to correct disease-causing alleles in inherited retinal disorders.
Genetic mutations are a risk factor for inherited retinal diseases. Diabetes is a risk factor for retinal microvascular disease such as retinopathy, and failure of retinal immune privilege with chronic inflammation is associated with retinal tissue damage.
The grounding supports imaging-based evaluation with optical coherence tomography angiography as an important modality for assessing retinal and choroidal blood flow. It also supports gene therapy approaches for selected inherited retinal diseases, especially AAV-based gene delivery and genome editing, and mentions glucose-lowering therapies such as GLP-1 receptor agonists and DPP-4 inhibitors in the context of diabetic microvascular complications, though not as established retinal-specific standard care.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases involving the RETINA.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.